Subtype
Gastroesophageal Junction Adenocarcinoma
CI-CAN-00005403Explore in graph →
228 active trials9 approved drugs25 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005403Explore in graph →
Clinical trials
696 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (82)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00061932 | Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Feb 2, 2021 | clinicaltrials |
| NCT03083613 | Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma | completed | Phase 2 | 41 | Chinese Academy of Medical SciencesOTHER | 1 | Feb 1, 2021 | clinicaltrials |
| NCT02234596 | Nintedanib in Patients With Advanced Esophagogastric Cancer | completed | Phase 2 | 34 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 25, 2021 | clinicaltrials |
| NCT02082210 | A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer | completed | Phase 1 / Phase 2 | 97 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT02443883 | A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer | completed | Phase 2 | 164 | Eli Lilly and CompanyINDUSTRY | 12 | Jun 29, 2020 | clinicaltrials |
| NCT02514551 | A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer | completed | Phase 2 | 245 | Eli Lilly and CompanyINDUSTRY | 11 | Jun 17, 2020 | clinicaltrials |
| NCT01362127 | Neoadjuvant Chemotherapy Versus Radiochemotherapy for Cancer of the Esophagus or Cardia(NeoRes) | completed | Phase 2 | 181 | Karolinska University HospitalOTHER | 1 | Feb 26, 2020 | clinicaltrials |
| NCT00515411 | Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma | completed | Phase 2 | 111 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 10, 2019 | clinicaltrials |
| NCT01498289 | S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer | completed | Phase 2 | 213 | SWOG Cancer Research NetworkNETWORK | 1 | Nov 7, 2019 | clinicaltrials |
| NCT01855854 | Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH | completed | Phase 2 | 54 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 5, 2019 | clinicaltrials |
| NCT01129310 | First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer.(IXOGoo1) | completed | Phase 2 | 47 | AHS Cancer Control AlbertaOTHER | 1 | Feb 25, 2019 | clinicaltrials |
| NCT00607594 | Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 2 | Aug 23, 2018 | clinicaltrials |
| NCT00891878 | Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction | completed | Phase 2 | 12 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 24, 2018 | clinicaltrials |
| NCT01757171 | Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma | completed | Phase 2 | 85 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 3, 2018 | clinicaltrials |
| NCT00938470 | Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction | completed | Phase 2 | 73 | Alliance for Clinical Trials in OncologyOTHER | 1 | Mar 29, 2018 | clinicaltrials |
| NCT01612546 | Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery | completed | Phase 2 | 10 | City of Hope Medical CenterOTHER | 1 | Feb 1, 2018 | clinicaltrials |
| NCT01178944 | Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer | completed | Phase 2 | 35 | Roswell Park Cancer InstituteOTHER | 1 | Dec 13, 2017 | clinicaltrials |
| NCT00062374 | Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jul 6, 2017 | clinicaltrials |
| NCT01472029 | Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach(HerFLOT) | completed | Phase 2 | 53 | AIO-Studien-gGmbHOTHER | 1 | Jun 19, 2017 | clinicaltrials |
| NCT01231399 | Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer | completed | Phase 1 / Phase 2 | 6 | City of Hope Medical CenterOTHER | 1 | May 31, 2017 | clinicaltrials |
| NCT01129206 | Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy | completed | Phase 2 | 6 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 1, 2016 | clinicaltrials |
| NCT01360086 | Fluorouracil, Cisplatin, Leucovorin Calcium, and Cetuximab in Treating Patients With Adenocarcinoma of the Stomach or Gastroesophageal Junction | completed | Phase 2 | 65 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | May 30, 2016 | clinicaltrials |
| NCT00849615 | Prospective Study With FLOT in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction(FLOT3) | completed | Phase 2 | 252 | Krankenhaus NordwestOTHER | 1 | Apr 6, 2016 | clinicaltrials |
| NCT00757172 | Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction | completed | Phase 2 | 70 | Alliance for Clinical Trials in OncologyOTHER | 1 | Mar 11, 2016 | clinicaltrials |
| NCT00982592 | Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer | completed | Phase 2 | 124 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2016 | clinicaltrials |
| NCT01260701 | Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer | completed | Phase 2 | 75 | National Cancer Institute (NCI)NIH | 2 | Jan 18, 2016 | clinicaltrials |
| NCT01932580 | Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Gastroesophageal Adenocarcinoma | completed | Phase 2 | 10 | McGill UniversityOTHER | 1 | Oct 27, 2015 | clinicaltrials |
| NCT01336062 | Trial of ABI-007 Plus S-1 as Second-line Chemotherapy in Advanced Gastric Cancer Patients | completed | Phase 1 / Phase 2 | 19 | Peking UniversityOTHER | 1 | May 19, 2015 | clinicaltrials |
| NCT00084617 | Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma | completed | Phase 2 | 39 | National Cancer Institute (NCI)NIH | 1 | May 1, 2015 | clinicaltrials |
| NCT00253370 | Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Nov 24, 2014 | clinicaltrials |
| NCT00165490 | Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer | completed | Phase 2 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 10, 2014 | clinicaltrials |
| NCT01567618 | Dose-dense Biweekly Docetaxel Combined With 5-fluorouracil as First-line Treatment in Advanced Gastric Cancer(DaeMon) | completed | Phase 2 | 39 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Nov 7, 2014 | clinicaltrials |
| NCT00991952 | Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | May 26, 2014 | clinicaltrials |
| NCT00183911 | Study of 5-Fluorouracil and Leucovorin and Intra-abdominal Floxuridine Chemoradiation in Patients With Fully Resected Locally Advanced Gastric Adenocarcinoma | completed | Phase 2 | 25 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00719550 | AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer | completed | Phase 1 / Phase 2 | 130 | AmgenINDUSTRY | 0 | Dec 5, 2013 | clinicaltrials |
| NCT00464893 | Phase II Study With Catumaxomab in Patients With Gastric Cancer After Neoadjuvant CTx and Curative Resection | completed | Phase 2 | 70 | Neovii BiotechINDUSTRY | 4 | Dec 4, 2013 | clinicaltrials |
| NCT00077545 | 3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction | completed | Phase 2 | 39 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2013 | clinicaltrials |
| NCT01118845 | Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma | completed | Phase 2 | 63 | SymBio PharmaceuticalsINDUSTRY | 2 | Jul 4, 2013 | clinicaltrials |
| NCT00045526 | Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer | completed | Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00084604 | Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00103324 | S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
| NCT00737373 | Oxaliplatin and 5-Fluorouracil With or Without Docetaxel in Elderly Patients (>65 y) With Stomach and Esophagus Cancer | completed | Phase 2 | 143 | Krankenhaus NordwestOTHER | 1 | Sep 19, 2012 | clinicaltrials |
| NCT00411151 | Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer | completed | Phase 2 | 52 | Johannes Gutenberg University MainzOTHER | 1 | Jan 20, 2011 | clinicaltrials |
| NCT00165191 | Doxorubicin, Cisplatin, 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus | completed | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 28, 2009 | clinicaltrials |
| NCT00352833 | Safety and Efficacy Study With Catumaxomab in Patients After Curative Resection of a Gastric Adenocarcinoma | completed | Phase 2 | 40 | Neovii BiotechINDUSTRY | 1 | Oct 26, 2007 | clinicaltrials |
| NCT00073502 | Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer | completed | Phase 2 | 43 | OSI PharmaceuticalsINDUSTRY | 3 | Feb 22, 2006 | clinicaltrials |
Data updated 23 days agoSource updated Feb 2, 2021source: clinicaltrials